ADB-CHMINACA (also known as ADMB-CHMINACA and MAB-CHMINACA) is an
indazole-based
synthetic cannabinoid
Synthetic cannabinoids, or neocannabinoids, are a class of designer drug molecules that Binding affinity, bind to the same receptors to which cannabinoids (Tetrahydrocannabinol, THC, Cannabidiol, CBD and many others) in cannabis plants attach. Th ...
. It is a potent
agonist
An agonist is a chemical that activates a Receptor (biochemistry), receptor to produce a biological response. Receptors are Cell (biology), cellular proteins whose activation causes the cell to modify what it is currently doing. In contrast, an R ...
of the
CB1 receptor with a binding affinity of ''K''
i = 0.289 nM and was originally developed by
Pfizer
Pfizer Inc. ( ) is an American Multinational corporation, multinational Pharmaceutical industry, pharmaceutical and biotechnology corporation headquartered at The Spiral (New York City), The Spiral in Manhattan, New York City. Founded in 184 ...
in 2009 as an
analgesic
An analgesic drug, also called simply an analgesic, antalgic, pain reliever, or painkiller, is any member of the group of drugs used for pain management. Analgesics are conceptually distinct from anesthetics, which temporarily reduce, and in s ...
medication. It was identified in cannabinoid blends in Japan in early 2015.
Side effects
There have been a number of reported cases of deaths and hospitalizations in relation to this synthetic cannabinoid.
Legal status
In the United States, ADB-CHMINACA is a
Schedule I controlled substance. Prior to its listing at the federal level in 2018, Louisiana placed ADB-CHMINACA on its Schedule I list by emergency scheduling in 2014.
Sweden's public health agency suggested to classify ADB-CHMINACA as hazardous substance on November 10, 2014.
ADB-CHMINACA is listed in the Fifth Schedule of the Misuse of Drugs Act (MDA) and therefore illegal in Singapore as of May 2015.
ADB-CHMINACA is illegal in Switzerland as of December 2015.
Metabolism
Ten ADB-CHMINACA major metabolites were identified in several incubations with cryopreserved human hepatocytes. Most transformations occurred at the cyclohexylmethyl tail of the compound.
See also
*
5F-AB-PINACA
*
5F-ADB
5F-ADB (also known as MDMB-5F-PINACA using systematic EMCDDA nomenclature and 5F-MDMB-PINACA) is an indazole-based synthetic cannabinoid from the indazole-3-carboxamide family, which has been used as an active ingredient in synthetic cannabis ...
*
5F-AMB
*
5F-APINACA
*
AB-FUBINACA
AB-FUBINACA ( AMB-FUBINACA) is a psychoactive drug that acts as a potent agonist for the cannabinoid receptors, with ''K''i values of 0.9 nM at CB1 and 23.2 nM at CB2 and EC50 values of 1.8 nM at CB1 and 3.2 nM at CB2. I ...
*
AB-CHFUPYCA
AB-CHFUPYCA (also AB-CHMFUPPYCA) is a compound that was first identified as a component of synthetic cannabis products in Japan in 2015. The name "AB-CHFUPYCA" is an acronym of its systematic name ''N''-(1-Amino-3-methyl-1-oxoButan-2-yl)-1-(Cycl ...
*
AB-CHMINACA
*
AB-PINACA
*
ADB-BINACA
*
ADB-FUBINACA
ADB-FUBINACA (ADMB-FUBINACA) is a designer drug identified in synthetic cannabis blends in Japan in 2013. In 2018, it was the third-most common synthetic cannabinoid identified in drugs seized by the Drug Enforcement Administration.
The name ...
*
ADB-HEXINACA
*
ADB-PINACA
ADB-PINACA is a cannabinoid designer drug that is an ingredient in some synthetic cannabis products. It is a potent agonist of the CB1 receptor and CB2 receptor with EC50 values of 0.52 nM and 0.88 nM respectively. Like MDMB-FUBIN ...
*
ADBICA
ADBICA (also known as ADB-PICA) is a designer drug identified in synthetic cannabis blends in Japan in 2013. ADBICA had not previously been reported in the scientific literature prior to its sale as a component of synthetic cannabis blends. ADBI ...
*
APICA
*
APINACA
APINACA (AKB48, ''N''-(1-adamantyl)-1-pentyl-1''H''-indazole-3-carboxamide) is a drug that acts as a reasonably potent agonist for the cannabinoid receptors. It is a full agonist at CB1 with an EC50 of 142 nM and Ki of 3.24 nM (compared to the ...
*
MDMB-CHMICA
*
MDMB-CHMINACA
*
MDMB-FUBINACA
*
PX-3
PX-3 (also known as APP-CHMINACA) is an indazole-based synthetic cannabinoid. It is a potent agonist of the CB1 receptor with a binding affinity of ''K''i = 47.6 nM and was originally developed by Pfizer in 2009 as an analgesic m ...
References
{{Cannabinoidergics
Cannabinoids
Designer drugs
Indazolecarboxamides
Cyclohexyl compounds
Carboxamides